Scarica l'app Stockscreener
1.73
0.00%
0.00
Dopo l'orario di chiusura:
1.70
-0.03
-1.73%
Precedente Chiudi:
$1.73
Aprire:
$1.73
Volume 24 ore:
641.63K
Relative Volume:
0.30
Capitalizzazione di mercato:
$275.07M
Reddito:
$10.00M
Utile/perdita netta:
$-29.47M
Rapporto P/E:
-8.65
EPS:
-0.2
Flusso di cassa netto:
$-21.55M
1 W Prestazione:
-1.14%
1M Prestazione:
+4.22%
6M Prestazione:
-30.52%
1 anno Prestazione:
-60.23%
Intervallo 1D:
$1.675
$1.74
Intervallo di 1 settimana:
$1.66
$1.83
Portata 52W:
$1.47
$4.72
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Nome
Mereo Biopharma Group Plc Adr
Settore
Industria
Telefono
4403330237300
Indirizzo
ONE CAVENDISH PLACE, LONDON
Confronta MREO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
1.73 | 281.43M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-27 | Iniziato | JP Morgan | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-06-13 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-13 | Ripresa | BTIG Research | Buy |
| 2022-08-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-05 | Iniziato | BTIG Research | Buy |
| 2021-04-05 | Iniziato | Needham | Buy |
Mostra tutto
Mereo Biopharma Group Plc Adr Borsa (MREO) Ultime notizie
Pomerantz LLP investigates Mereo BioPharma securities fraud claims. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - cnhinews.com
JPMorgan Chase & Co. Issues Positive Forecast for Mereo BioPharma Group (NASDAQ:MREO) Stock Price - Defense World
Mereo BioPharma Group plc investigated for securities fraud and unlawful practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
FY2026 EPS Estimates for MREO Lifted by Cantor Fitzgerald - Defense World
Leerink Partnrs Has Negative Outlook for MREO Q3 Earnings - Defense World
Analysts Offer Predictions for MREO Q3 Earnings - Defense World
Mereo BioPharma Group faces securities fraud investigation. - AInvest
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Receives Average Rating of “Buy” from Analysts - Defense World
Mereo BioPharma ADR earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK
Mereo BioPharma Reports Q2 2025 Financial Results and Updates on Setrusumab Phase 3 Studies for Osteogenesis Imperfecta - Quiver Quantitative
Mereo's Setrusumab Phase 3 Trials Hit Key Safety Milestone: Year-End Results Coming for Rare Bone Disease - Stock Titan
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Pomerantz LLP Investigates Mereo BioPharma Group Securities Fraud Claims. - AInvest
Pomerantz LLP investigates Mereo BioPharma Group securities fraud claims. - AInvest
Mereo BioPharma investigated for potential securities fraud. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Connect - ACCESS Newswire
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Mereo BioPharma Group plc (MREO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Mereo BioPharma Group plc (MREO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Investors in Mereo BioPharma Group plc (MREO) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
MREO ACTIVE INVESTIGATION: Lost Money on Mereo BioPharma Group plc? Contact Levi & Korsinsky Now - ACCESS Newswire
ATTENTION MREO Shareholders: Lost Money on Mereo BioPharma Group plc? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Investigation Opened on Behalf of Mereo BioPharma Group plc (MREO) ShareholdersContact Levi & Korsinsky - ACCESS Newswire
Ongoing Securities Investigation into Mereo BioPharma Group plc (MREO)Contact Levi & Korsinsky - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Stockholders to Connect - ACCESS Newswire
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Consensus Rating of “Buy” by Brokerages - Defense World
Investigation Underway: Mereo BioPharma Group plc (MREO)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
MREO ALERT: Ongoing Investigation Into Mereo BioPharma Group plcContact Levi & Korsinsky - ACCESS Newswire
Protect Your Investment: Contact Levi & Korsinsky About the Mereo BioPharma Group plc (MREO) Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
BTIG reiterates Buy rating on Mereo BioPharma stock amid trial progress By Investing.com - Investing.com South Africa
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.43% - Investing.com
United States shares higher at close of trade; Dow Jones Industrial Average up 0.43% - Investing.com India
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End - Yahoo Finance
JPMorgan maintains Mereo BioPharma stock rating despite trial setback By Investing.com - Investing.com India
JPMorgan maintains Mereo BioPharma stock rating despite trial setback - Investing.com
Mereo BioPharma and Ultragenyx advance Phase 3 Orbit study for osteogenesis imperfecta - Investing.com India
Mereo Biopharma Group Plc Adr Azioni (MREO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mereo Biopharma Group Plc Adr Azioni (MREO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Scots-Knight Denise | Chief Executive Officer |
Sep 12 '24 |
Sale |
4.47 |
28,611 |
127,968 |
868,967 |
| Lewicki John A. | Chief Scientific Officer |
Sep 13 '24 |
Sale |
4.22 |
10,937 |
46,165 |
78,630 |
| Lewicki John A. | Chief Scientific Officer |
Sep 12 '24 |
Sale |
4.47 |
5,212 |
23,312 |
89,567 |
| Sermon Charles | General Counsel |
Sep 13 '24 |
Sale |
4.22 |
20,946 |
88,413 |
219,061 |
| Sermon Charles | General Counsel |
Sep 12 '24 |
Sale |
4.47 |
9,980 |
44,638 |
240,007 |
| Fox Christine Ann | Chief Financial Officer |
Sep 13 '24 |
Sale |
4.22 |
19,158 |
80,866 |
89,285 |
| Fox Christine Ann | Chief Financial Officer |
Sep 12 '24 |
Sale |
4.47 |
9,128 |
40,827 |
108,443 |
| Hughes-Wilson Alexandra | See Remarks |
Sep 13 '24 |
Sale |
4.22 |
100,312 |
423,417 |
50,475 |
| Hughes-Wilson Alexandra | See Remarks |
Sep 12 '24 |
Sale |
4.47 |
47,798 |
213,786 |
150,787 |
| Sermon Charles | General Counsel |
Sep 11 '24 |
Option Exercise |
0.00 |
65,600 |
0 |
249,987 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):